Search - tctmd.com

Displaying 61 - 80 of 427

Sort: Relevancy | Date

News Daily News

TAVI vs Minimally Invasive AVR Yields Surprising Findings: Meta-analysis

Yael L. Maxwell

January 22, 2021

News Conference News TCT 2020

Encouraging Results Seen for TAVR in Failed Surgical or TAVR Valves

Todd Neale

October 17, 2020

News Conference News TCT 2020

Sapien 3 Stroke Rate Perplexes in 1-Year SOLVE-TAVI Results

Michael O'Riordan

October 16, 2020

News Daily News

PARTNER Data Back 5-Year Durability of Sapien 3 TAVR

Caitlin E. Cox

October 12, 2020

News Daily News

Renal Function Gains Seen in CKD Patients After TAVR

L.A. McKeown

September 15, 2020

News Daily News

TAVR and Infective Endocarditis—Two Studies Address a Shifting Landscape

Caitlin E. Cox

September 14, 2020

News Daily News

Which TAVR Device Is Best? Review Tackles Optimal Selection

Michael O'Riordan

September 09, 2020

News Daily News

Should Guidelines Support TAVR for Low-Risk Patients? Two Views

L.A. McKeown

August 17, 2020

News Conference News TVT 2020

Sapien 3 in Intermediate Risk: Death or Stroke Similar to SAVR at 5 Years

Michael O'Riordan

June 22, 2020

Presentation TVT 2020

SAPIEN 3 Transcatheter Aortic Valve Replacement Compared with Surgery in Intermediate-risk Patients: A Propensity-Matched Analysis of 5-year Outcomes

Presenter: Susheel K. Kodali

June 21, 2020

News Conference News TVT 2020

Skipping Predilatation in Low-risk TAVR Patients Does Not Mar Outcomes

L.A. McKeown

June 19, 2020

News Daily News

LV Mass Regression After TAVR Linked to Better Long-term Outcomes

Michael O'Riordan

May 13, 2020

News Conference News ACC 2020

Early Data Support TAVR in Bicuspid Valves, but Questions Remain

Michael O'Riordan

March 29, 2020

News Conference News ACC 2020

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

Yael L. Maxwell

March 29, 2020

News Conference News CRT 2020

Retrospective Analysis Isolates Predictors of Late Pacemaker Need Post-TAVR

L.A. McKeown

March 06, 2020

News Conference News CRT 2020

Small Study Hints Rivaroxaban Helps Cut Stroke in A-fib Patients Post-TAVR

L.A. McKeown

February 24, 2020

News Conference News STS 2020

For Congenital Heart Disease, SAVR With Bioprosthetic Valve Still Reigns

Yael L. Maxwell

January 30, 2020

News Conference News STS 2020

TAVR Tussle at US Surgery Meeting Threatens to Widen Surgeon-Cardiologist Wedge

Yael L. Maxwell

January 29, 2020

News Features

Year in Review: Low-Risk TAVR Trials Big in 2019, but QoL Data Impresses, Too

Michael O'Riordan

December 18, 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

Advertisement

TAVI vs Minimally Invasive AVR Yields Surprising Findings: Meta-analysis

Encouraging Results Seen for TAVR in Failed Surgical or TAVR Valves

Sapien 3 Stroke Rate Perplexes in 1-Year SOLVE-TAVI Results

PARTNER Data Back 5-Year Durability of Sapien 3 TAVR

Renal Function Gains Seen in CKD Patients After TAVR

TAVR and Infective Endocarditis—Two Studies Address a Shifting Landscape

Which TAVR Device Is Best? Review Tackles Optimal Selection

Should Guidelines Support TAVR for Low-Risk Patients? Two Views

Sapien 3 in Intermediate Risk: Death or Stroke Similar to SAVR at 5 Years

SAPIEN 3 Transcatheter Aortic Valve Replacement Compared with Surgery in Intermediate-risk Patients: A Propensity-Matched Analysis of 5-year Outcomes

Skipping Predilatation in Low-risk TAVR Patients Does Not Mar Outcomes

LV Mass Regression After TAVR Linked to Better Long-term Outcomes

Early Data Support TAVR in Bicuspid Valves, but Questions Remain

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

Retrospective Analysis Isolates Predictors of Late Pacemaker Need Post-TAVR

Small Study Hints Rivaroxaban Helps Cut Stroke in A-fib Patients Post-TAVR

For Congenital Heart Disease, SAVR With Bioprosthetic Valve Still Reigns

TAVR Tussle at US Surgery Meeting Threatens to Widen Surgeon-Cardiologist Wedge

Year in Review: Low-Risk TAVR Trials Big in 2019, but QoL Data Impresses, Too

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content